Vanguard Group Inc boosted its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 1.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,970,746 shares of the medical device company’s stock after buying an additional 101,806 shares during the period. Vanguard Group Inc owned 8.95% of NxStage Medical worth $166,523,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of NXTM. Kite Lake Capital Management UK LLP increased its holdings in shares of NxStage Medical by 228.3% during the third quarter. Kite Lake Capital Management UK LLP now owns 1,151,980 shares of the medical device company’s stock valued at $32,128,000 after purchasing an additional 801,048 shares during the period. BlackRock Inc. increased its holdings in shares of NxStage Medical by 10.5% during the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock valued at $147,581,000 after purchasing an additional 501,922 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of NxStage Medical by 56.3% during the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock valued at $33,113,000 after purchasing an additional 427,745 shares during the period. Manikay Partners LLC acquired a new position in shares of NxStage Medical during the third quarter valued at $11,853,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of NxStage Medical during the third quarter valued at $7,792,000. 83.49% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have recently commented on the company. BidaskClub lowered NxStage Medical from a “buy” rating to a “hold” rating in a report on Wednesday, November 28th. ValuEngine raised NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Finally, Zacks Investment Research raised NxStage Medical from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th.
NxStage Medical (NASDAQ:NXTM) last released its earnings results on Wednesday, November 7th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $108.12 million for the quarter, compared to analyst estimates of $108.07 million. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. Analysts anticipate that NxStage Medical, Inc. will post 0.06 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2019/01/11/vanguard-group-inc-has-166-52-million-holdings-in-nxstage-medical-inc-nxtm.html.
NxStage Medical Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.